On this page
What each program costs in Virginia
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Commonwealth of Virginia state employee health plan cover GLP-1s for weight loss?
Virginia's state employee health plans require a BMI of 35 or higher, plus prior authorization, for a weight-loss GLP-1 under the criteria announced for the 2026 open enrollment.
Does Virginia Medicaid (Cardinal Care) cover GLP-1s for weight loss?
Covered, with conditions
Virginia Medicaid's weight-loss form effective October 20, 2026 covers Wegovy and Zepbound with authorization for BMI over 40, or over 37 with a listed risk factor. Read from state documents Nov 6, 2026.
What Virginia Medicaid (Cardinal Care)'s documents say about each drug for weight loss. Read Nov 6, 2026. Virginia Department of Medical Assistance Services.
WegovyYes
Service authorization. BMI over 40, or over 37 with high cholesterol, high blood pressure or type 2 diabetes. Must have failed one non-GLP-1 weight-loss drug or be intolerant to all of them, and the provider attests obesity is disabling and life threatening. Ages by product. A separate form covers heart risk.
“(Wegovy/Saxenda injections [min age 12]), (Wegovy HD/tablet [min age 18], Zepbound [min age 18 and member must try and fail Zepbound KwikPen prior to approval of Zepbound unit dose pen])”
Virginia Department of Medical Assistance Services, via Prime Therapeutics · Effective Oct 20, 2026 · read Nov 6, 2026
“BMI > 40 kg/m2 if no applicable risk factors; OR”
Virginia Department of Medical Assistance Services, via Prime Therapeutics · Effective Oct 20, 2026 · read Nov 6, 2026
“BMI > 37 kg/m2 with one or more of the following risk factors: dyslipidemia, hypertension, or type 2 diabetes”
Virginia Department of Medical Assistance Services, via Prime Therapeutics · Effective Oct 20, 2026 · read Nov 6, 2026
“The provider attests that the patient's obesity is disabling and life threatening”
Virginia Department of Medical Assistance Services, via Prime Therapeutics · Effective Oct 20, 2026 · read Nov 6, 2026
ZepboundYes
Service authorization. BMI over 40, or over 37 with high cholesterol, high blood pressure or type 2 diabetes. Must have failed one non-GLP-1 weight-loss drug or be intolerant to all of them, and the provider attests obesity is disabling and life threatening. Age 18 and older, and KwikPen is tried before the unit dose pen.
“(Wegovy/Saxenda injections [min age 12]), (Wegovy HD/tablet [min age 18], Zepbound [min age 18 and member must try and fail Zepbound KwikPen prior to approval of Zepbound unit dose pen])”
Virginia Department of Medical Assistance Services, via Prime Therapeutics · Effective Oct 20, 2026 · read Nov 6, 2026
“BMI > 40 kg/m2 if no applicable risk factors; OR”
Virginia Department of Medical Assistance Services, via Prime Therapeutics · Effective Oct 20, 2026 · read Nov 6, 2026
“BMI > 37 kg/m2 with one or more of the following risk factors: dyslipidemia, hypertension, or type 2 diabetes”
Virginia Department of Medical Assistance Services, via Prime Therapeutics · Effective Oct 20, 2026 · read Nov 6, 2026
“The provider attests that the patient's obesity is disabling and life threatening”
Virginia Department of Medical Assistance Services, via Prime Therapeutics · Effective Oct 20, 2026 · read Nov 6, 2026
OzempicNot confirmed
The newest PDL criteria found is dated 1/1/25, where this drug is not in the preferred column, and its type II diabetes rule is stated for preferred agents. The Non-Preferred Incretin Mimetics form was not found, and 2026 PDL criteria URLs returned 404.
MounjaroNot confirmed
The newest PDL criteria found is dated 1/1/25, where this drug is not in the preferred column, and its type II diabetes rule is stated for preferred agents. The Non-Preferred Incretin Mimetics form was not found, and 2026 PDL criteria URLs returned 404.
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Virginia Department of Medical Assistance Services documents. KFF's January 2026 map listed this program as covered; the documents we read agree.
Weight loss
Covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
44,787 prescriptions
Ozempic and Mounjaro, 2025
56,550 prescriptions
Neighbours covering weight loss
2 of 6
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Virginia Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Virginia Medicaid as "covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Virginia Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Virginia Medicaid pay for?
227,472 GLP-1 prescriptions in 2025, 14th of the 50 states and DC, with $221.5 million reimbursed before rebates. Counting the share other payers covered, $230.0 million.
Prescriptions, 2025
227,472
14th of 51
Medicaid paid
$221.5M
14th of 51, before rebates
Per prescription
$974
$1,051 nationally
Weight-loss brands
20%
15th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Virginia is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 20% of Virginia Medicaid's GLP-1 prescriptions in 2025 (44,787). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Trulicity was Virginia Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Trulicity | 115,903 | 51% | $112.7 million | $972 |
| Ozempic | 28,955 | 13% | $26.1 million | $903 |
| Mounjaro | 27,595 | 12% | $26.3 million | $954 |
| Wegovyapproved for weight management | 24,209 | 11% | $29.2 million | $1,205 |
| Zepboundapproved for weight management | 11,795 | 5.2% | $10.6 million | $895 |
| Saxendaapproved for weight management | 8,783 | 3.9% | $10.1 million | $1,154 |
| Liraglutide (generic) | 3,928 | 1.7% | $1.8 million | $461 |
| Victoza | 3,609 | 1.6% | $2.2 million | $597 |
| Rybelsus | 2,396 | 1.1% | $2.2 million | $924 |
| Byetta | 178 | 0.1% | $146,984 | $826 |
| Bydureon | 68 | 0.0% | $52,886 | $778 |
| Exenatide (generic) | 53 | 0.0% | $36,426 | $687 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in Virginia?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 2 in Virginia. The register does not say which, if any, supplies a program on this page.
- Annovex Pharma, Inc., Lorton. Registered since Oct 14, 2021; last FDA inspection Jun 3, 2026.
- WeCare Pharmaceutical Corp dba WeCare Pharmaceuticals, Chantilly. Registered since Oct 28, 2026; not yet inspected by FDA.
On Medicare in Virginia?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Virginia and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
2 of the 6 states next to Virginia cover GLP-1s for weight loss through Medicaid: North Carolina and Tennessee. None has a lower cash floor than Virginia's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Virginia | Covered | 19 | $39/mo |
| Kentucky | Not covered | 19 | $39/moWellmedr |
| Maryland | Not covered | 19 | $39/moWellmedr |
| North Carolina | Covered | 19 | $39/moWellmedr |
| Tennessee | Covered | 18 | $39/moWellmedr |
| West Virginia | Not covered | 18 | $39/moWellmedr |
| Washington, DC | Not covered | 0 | none verified |






















